Walmart Inc. (NASDAQ:WMT) shares are recovering on Friday after declining on Thursday following its third-quarter results.
It reported an adjusted EPS of 65 cents, exceeding analyst expectations of 64 cents. The figure excludes an after-tax loss of 3 cents per share related to equity and other investments.
Revenue rose 5.2% year over year to $188.835 billion, topping the consensus estimate of $187.271 billion.
However, Walmart’s weight-loss drug windfall is losing momentum despite rising prescription volumes.
Analyst Price Forecast Revisions
Several analysts raised their price forecasts following Walmart’s third-quarter results and increased guidance, while maintaining their existing ratings.
- Morgan Stanley analyst Simeon Gutman maintained an Overweight rating and raised his price forecast to $135 from $125.
- Piper Sandler analyst Peter Keith maintained an Overweight rating and increased his price forecast to $138 from $128.
- TD Cowen analyst Max Rakhlenko maintained a Buy rating and raised his price forecast to $147 from $125.
- Truist Securities analyst Scot Ciccarelli maintained a Buy rating and increased his price forecast to $134 from $114.
- BTIG analyst Robert Drbul reiterated a Buy rating and maintained his $140 price forecast.
BTIG Analyst View
Drbul believes Walmart’s underlying U.S. business remains healthy, although Health & Wellness (H&W) is expected to weigh on reported comparable sales.
Walmart’s 2.9% U.S. comparable sales growth included an approximately 125-basis-point drag from Maximum Fair Price-related pharmacy deflation and brand-to-generic transfers, partly offset by a roughly 60-basis-point contribution from GLP-1 drugs.
Excluding H&W, comparable sales increased 3.6%, slightly accelerating from the second quarter of fiscal 2027 and improving on a two-year basis.
Looking ahead, the analyst expects healthy underlying demand but anticipates continued pressure on reported comparable sales from H&W.
MFP-related headwinds are expected to remain near current levels or increase slightly, while the contribution from GLP-1 drugs is likely to moderate.
However, improving H&W gross profit margins should help cushion the impact of weaker reported sales, according to the analyst.
Earnings Estimates And Outlook
Drbul maintained his fiscal 2027 EPS estimate at $2.90 but lowered his fourth-quarter Walmart U.S. comparable sales growth forecast to 2.9% from 3.1%. He expects comparable sales to increase 3.6% excluding H&W.
The analyst expects fiscal 2027 net sales of $748 billion, representing approximately 6% year-over-year growth, with operating income projected to grow faster than sales.
For fiscal 2028, Drbul raised his EPS estimate to $3.25 from $3.15.
WMT Price Action: Walmart shares were up 2.82% at $129.60 at the time of publication on Friday, according to Benzinga Pro data.
Photo via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.



